Ono and DSP look to extend limaprost franchise through carpal tunnel deal
This article was originally published in Scrip
Executive Summary
Ono will be hoping to shore up the sales of its top-selling product through an agreement with Dainippon Sumitomo Pharma to develop and market jointly in Japan limaprost alfadex for the new indication of carpal tunnel syndrome (CTS).